SHIFT

Systolic Heart failure treatment with the lf inhibitor ivabradine Trial

Skip to content
  • Home
  • SHIFT
  • IVABRADINE
  • HEART RATE & HEART FAILURE
  • NEWSROOM
  • RESOURCES
  • CONTACT US
Home > newsroom > Latest publications on SHIFT

Latest publications on SHIFT

  • SHIFT is the basis for a prognostic model for heart failure patients
  • Ivabradine safely and significantly improves heart rate variability parameters
  • The efficacy and safety of ivabradine is independent of baseline blood pressure
  • Ivabradine’s clinical benefits in CHF are maintained with or without renal dysfunction
  • Ivabradine improves clinical outcomes independently of heart failure severity
  • Ivabradine is similarly effective in chronic heart failure patients with or without COPD
  • Age does not limit the appropriate use of ivabradine in patients with chronic heart failure and systolic dysfunction
This website is intended for an international audience. Drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information. This site is published and updated by the SHIFT study investigators-©2021 SHIFT. All rights reserved. Report a side-effect with a drug.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more